Cargando…
Antioxidant Effects of PS5, a Peptidomimetic of Suppressor of Cytokine Signaling 1, in Experimental Atherosclerosis
The chronic activation of the Janus kinase/signal transducer and activator of the transcription (JAK/STAT) pathway is linked to oxidative stress, inflammation and cell proliferation. Suppressors of cytokine signaling (SOCS) proteins negatively regulate the JAK/STAT, and SOCS1 possesses a small kinas...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465353/ https://www.ncbi.nlm.nih.gov/pubmed/32824091 http://dx.doi.org/10.3390/antiox9080754 |
_version_ | 1783577569844527104 |
---|---|
author | La Manna, Sara Lopez-Sanz, Laura Bernal, Susana Jimenez-Castilla, Luna Prieto, Ignacio Morelli, Giancarlo Gomez-Guerrero, Carmen Marasco, Daniela |
author_facet | La Manna, Sara Lopez-Sanz, Laura Bernal, Susana Jimenez-Castilla, Luna Prieto, Ignacio Morelli, Giancarlo Gomez-Guerrero, Carmen Marasco, Daniela |
author_sort | La Manna, Sara |
collection | PubMed |
description | The chronic activation of the Janus kinase/signal transducer and activator of the transcription (JAK/STAT) pathway is linked to oxidative stress, inflammation and cell proliferation. Suppressors of cytokine signaling (SOCS) proteins negatively regulate the JAK/STAT, and SOCS1 possesses a small kinase inhibitory region (KIR) involved in the inhibition of JAK kinases. Several studies showed that KIR-SOCS1 mimetics can be considered valuable therapeutics in several disorders (e.g., diabetes, neurological disorders and atherosclerosis). Herein, we investigated the antioxidant and atheroprotective effects of PS5, a peptidomimetic of KIR-SOCS1, both in vitro (vascular smooth muscle cells and macrophages) and in vivo (atherosclerosis mouse model) by analyzing gene expression, intracellular O(2)(•−) production and atheroma plaque progression and composition. PS5 was revealed to be able to attenuate NADPH oxidase (NOX1 and NOX4) and pro-inflammatory gene expression, to upregulate antioxidant genes and to reduce atheroma plaque size, lipid content and monocyte/macrophage accumulation. These findings confirm that KIR-SOCS1-based drugs could be excellent antioxidant agents to contrast atherosclerosis. |
format | Online Article Text |
id | pubmed-7465353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74653532020-09-04 Antioxidant Effects of PS5, a Peptidomimetic of Suppressor of Cytokine Signaling 1, in Experimental Atherosclerosis La Manna, Sara Lopez-Sanz, Laura Bernal, Susana Jimenez-Castilla, Luna Prieto, Ignacio Morelli, Giancarlo Gomez-Guerrero, Carmen Marasco, Daniela Antioxidants (Basel) Article The chronic activation of the Janus kinase/signal transducer and activator of the transcription (JAK/STAT) pathway is linked to oxidative stress, inflammation and cell proliferation. Suppressors of cytokine signaling (SOCS) proteins negatively regulate the JAK/STAT, and SOCS1 possesses a small kinase inhibitory region (KIR) involved in the inhibition of JAK kinases. Several studies showed that KIR-SOCS1 mimetics can be considered valuable therapeutics in several disorders (e.g., diabetes, neurological disorders and atherosclerosis). Herein, we investigated the antioxidant and atheroprotective effects of PS5, a peptidomimetic of KIR-SOCS1, both in vitro (vascular smooth muscle cells and macrophages) and in vivo (atherosclerosis mouse model) by analyzing gene expression, intracellular O(2)(•−) production and atheroma plaque progression and composition. PS5 was revealed to be able to attenuate NADPH oxidase (NOX1 and NOX4) and pro-inflammatory gene expression, to upregulate antioxidant genes and to reduce atheroma plaque size, lipid content and monocyte/macrophage accumulation. These findings confirm that KIR-SOCS1-based drugs could be excellent antioxidant agents to contrast atherosclerosis. MDPI 2020-08-14 /pmc/articles/PMC7465353/ /pubmed/32824091 http://dx.doi.org/10.3390/antiox9080754 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article La Manna, Sara Lopez-Sanz, Laura Bernal, Susana Jimenez-Castilla, Luna Prieto, Ignacio Morelli, Giancarlo Gomez-Guerrero, Carmen Marasco, Daniela Antioxidant Effects of PS5, a Peptidomimetic of Suppressor of Cytokine Signaling 1, in Experimental Atherosclerosis |
title | Antioxidant Effects of PS5, a Peptidomimetic of Suppressor of Cytokine Signaling 1, in Experimental Atherosclerosis |
title_full | Antioxidant Effects of PS5, a Peptidomimetic of Suppressor of Cytokine Signaling 1, in Experimental Atherosclerosis |
title_fullStr | Antioxidant Effects of PS5, a Peptidomimetic of Suppressor of Cytokine Signaling 1, in Experimental Atherosclerosis |
title_full_unstemmed | Antioxidant Effects of PS5, a Peptidomimetic of Suppressor of Cytokine Signaling 1, in Experimental Atherosclerosis |
title_short | Antioxidant Effects of PS5, a Peptidomimetic of Suppressor of Cytokine Signaling 1, in Experimental Atherosclerosis |
title_sort | antioxidant effects of ps5, a peptidomimetic of suppressor of cytokine signaling 1, in experimental atherosclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465353/ https://www.ncbi.nlm.nih.gov/pubmed/32824091 http://dx.doi.org/10.3390/antiox9080754 |
work_keys_str_mv | AT lamannasara antioxidanteffectsofps5apeptidomimeticofsuppressorofcytokinesignaling1inexperimentalatherosclerosis AT lopezsanzlaura antioxidanteffectsofps5apeptidomimeticofsuppressorofcytokinesignaling1inexperimentalatherosclerosis AT bernalsusana antioxidanteffectsofps5apeptidomimeticofsuppressorofcytokinesignaling1inexperimentalatherosclerosis AT jimenezcastillaluna antioxidanteffectsofps5apeptidomimeticofsuppressorofcytokinesignaling1inexperimentalatherosclerosis AT prietoignacio antioxidanteffectsofps5apeptidomimeticofsuppressorofcytokinesignaling1inexperimentalatherosclerosis AT morelligiancarlo antioxidanteffectsofps5apeptidomimeticofsuppressorofcytokinesignaling1inexperimentalatherosclerosis AT gomezguerrerocarmen antioxidanteffectsofps5apeptidomimeticofsuppressorofcytokinesignaling1inexperimentalatherosclerosis AT marascodaniela antioxidanteffectsofps5apeptidomimeticofsuppressorofcytokinesignaling1inexperimentalatherosclerosis |